ERYDEL

Summary

EryDel SpA is a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 419 M

Avg. Deal Size£ 419 M

Market Context

Senior Management

Luca Benatti
CEO
Stanley Musial
CFO